Elevation Oncology Stock Revenue
| ELEV Stock | USD 0.48 0.05 9.43% |
Elevation Oncology fundamentals help investors to digest information that contributes to Elevation Oncology's financial success or failures. It also enables traders to predict the movement of Elevation Stock. The fundamental analysis module provides a way to measure Elevation Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elevation Oncology stock.
| Last Reported | Projected for Next Year |
Elevation | Revenue |
Elevation Oncology Company Revenue Analysis
Elevation Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Elevation
Projected quarterly revenue analysis of Elevation Oncology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Elevation Oncology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Elevation Oncology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Elevation Oncology reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Elevation Oncology is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 0.0. Elevation Oncology adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Elevation Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Elevation Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Elevation Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Elevation Oncology's value.| Shares | Orbimed Advisors, Llc | 2024-12-31 | 941.3 K | Millennium Management Llc | 2024-12-31 | 815.9 K | Ikarian Capital, Llc | 2024-12-31 | 690 K | Ameriprise Financial Inc | 2024-12-31 | 444 K | Northern Trust Corp | 2024-12-31 | 432.6 K | Allostery Investments Lp | 2024-12-31 | 432.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 420.4 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 333.3 K | Citadel Advisors Llc | 2024-12-31 | 266.2 K | Tang Capital Management Llc | 2024-12-31 | 4.8 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 3.5 M |
Elevation Fundamentals
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (30.91 M) | ||||
| Shares Outstanding | 59.22 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 67.76 % | ||||
| Number Of Shares Shorted | 8.79 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.52 X | ||||
| EBITDA | (44.7 M) | ||||
| Net Income | (44.48 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 31.13 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (36.36 M) | ||||
| Short Ratio | 6.75 X | ||||
| Earnings Per Share | (0.78) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 34 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 31.14 M | ||||
| Total Asset | 95.63 M | ||||
| Retained Earnings | (240.46 M) | ||||
| Working Capital | 90.26 M | ||||
| Net Asset | 95.63 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.